Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 June 2019 | Story Leonie Bolleurs | Photo Barend Nagel
Marnus du Plooy
Marnus du Plooy, recipient of a Fulbright Scholarship, will depart for the Duke University in Durham, North Carolina, in August to complete a doctoral degree.

Marnus du Plooy will receive his master’s degree at the University of the Free State’s Winter Graduation Ceremony.

After completing his BSc degree in Microbiology, he discovered a passion for this field of research and enrolled for postgraduate studies in the Department of Microbial, Biochemical and Food Biotechnology at the UFS.

During his master’s, Du Plooy focused on the pathogenic yeasts, Cryptococcus neoformans and a related species, C. deneoformans.

Passion for science instilled at a young age

His passion for this field comes from a young age. “Both my parents were Science teachers and they instilled a love for Science in me. At school, I enjoyed the Science subjects the most and usually obtained my highest marks in these,” Du Plooy said. 

The pathogenic yeasts studied by Du Plooy, Cryptococcus neoformans and the sister species, C. deneoformans, often cause meningitis in immunocompromised individuals, such as in people living with HIV/Aids.

He pointed out: “Infection caused by these yeasts is right on the heels of TB as the second largest killer of HIV-positive patients in sub-Saharan Africa. The focus of my master’s project was to investigate new ways in which genes can be ‘switched off’ in these yeasts in order to study the role of the genes in virulence. Doing so could help to identify new drug targets for the treatment of this form of meningitis in subsequent studies.”

Expanding his international footprint

Although Du Plooy received his master’s degree from the UFS, he grabbed the opportunity to study abroad with both hands. He applied for and received a Fulbright scholarship from the Fulbright Foreign Student Programme, giving him the opportunity to study in the US.

“I did not expect to get very far with the application, as very few candidates are selected each year. I was very lucky to receive a Fulbright scholarship and an admission offer from Duke University for PhD studies in Microbiology,” said Du Plooy.

He hopes to continue with research on Cryptococcus and to contribute to improving the lives of HIV/Aids patients. “I have always been interested in pharmaceutical and medical research and noticed a need for better cryptococcal treatments, especially in sub-Saharan Africa. Cryptococcal meningitis is a neglected disease which claims more than 600 000 lives worldwide every year. The current treatment options are several decades old, with some only available in well-resourced areas.”

Du Plooy will depart for the US in August. “The duration of the degree is four to five years, where-after I will return to South Africa to apply what I have learned at home.”

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept